Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Molife, C. | - |
dc.contributor.author | Cho, J.M. | - |
dc.contributor.author | Lapthorn, J. | - |
dc.contributor.author | Kang, M.J. | - |
dc.contributor.author | D’yachkova, Y. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Colman, S. | - |
dc.contributor.author | Kim, S. | - |
dc.contributor.author | Szende, A. | - |
dc.contributor.author | Park, J.H. | - |
dc.contributor.author | Ahn, H.K. | - |
dc.contributor.author | Hong, M.H. | - |
dc.contributor.author | Taipale, K.-L. | - |
dc.contributor.author | Kim, H.R. | - |
dc.date.accessioned | 2023-03-02T01:40:06Z | - |
dc.date.available | 2023-03-02T01:40:06Z | - |
dc.date.created | 2022-12-12 | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 2199-1154 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86965 | - |
dc.description.abstract | Background: Despite the dynamic treatment landscape for EGFR mutant-positive metastatic non-small cell lung cancer (EGFRm+ mNSCLC), most of the earlier studies have focused on US or Western populations. Objective: The objective of this study was to explore real-world treatment patterns and outcomes of South Korean patients with EGFRm+ mNSCLC. Methods: Retrospective chart review of adult patients with EGFRm+ mNSCLC who received systemic treatment between January-2019 and June-2019. Results: A total of 162 patients were included from 21 hospitals, with a median follow-up of 15.6 months. Median age was 65.0 years, 22% had central nervous system metastasis, and 57% and 38% had exon 19 deletion and exon 21 L858R, respectively. Among 144 patients (89%) who received first-line EGFR-tyrosine kinase inhibitor, afatinib was most the common (44%), followed by gefitinib (28%) and erlotinib (13%). First-line chemotherapy was more common when an EGFR-mutation was detected after versus before first-line treatment initiation (31% vs 5%). Discontinuation of first-line treatment was mostly due to disease-progression (81%) and toxicity (7%). Among 58 (78%) patients who received second-line treatment, osimertinib was the most common (40%). Most (60%) patients reported ≥1 Grade ≥3 adverse event during first-line treatment. Following initiation of first-line treatment, physician visits and chest X-rays were the most frequent healthcare utilisation events. Rates of emergency-room visits and hospitalization were 12% and 16%, respectively, with a mean length-of-stay of 10.4 days. At 12 months, overall survival rate was 95%, and numerically worse for patients with exon 21 versus 19 mutations. Conclusions: Characteristics and clinical outcomes of Korean patients with EGFRm+ mNSCLC in real-world practice were comparable to those observed in clinical trials. As osimertinib was not reimbursed for first-line treatment before study completion, further investigation is warranted to explore evolving treatment practice. © 2022, The Author(s). | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Adis | - |
dc.relation.isPartOf | Drugs - Real World Outcomes | - |
dc.title | Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000912909400002 | - |
dc.identifier.doi | 10.1007/s40801-022-00344-0 | - |
dc.identifier.bibliographicCitation | Drugs - Real World Outcomes, v.10, no.1, pp.131 - 143 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85143290448 | - |
dc.citation.endPage | 143 | - |
dc.citation.startPage | 131 | - |
dc.citation.title | Drugs - Real World Outcomes | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Ahn, H.K. | - |
dc.type.docType | Article; Early Access | - |
dc.subject.keywordPlus | FACTOR RECEPTOR MUTATION | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | AFATINIB | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | ERLOTINIB | - |
dc.subject.keywordPlus | ADENOCARCINOMA | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.